Evaluating neoadjuvant therapy effectiveness on systemic disease: Use of a prostatic-specific membrane reverse transcription polymerase chain reaction
Sai L. Su(Memorial Sloan Kettering Cancer Center), William R. Fair(University of California System), Nicholas Stroumbakis(Memorial Sloan Kettering Cancer Center), Beth Brander(Memorial Sloan Kettering Cancer Center), Michael S. Cookson(University of Oklahoma Health Sciences Center), Elizabeth Edwards(Memorial Sloan Kettering Cancer Center), Scott M. Soloway(Memorial Sloan Kettering Cancer Center), Michael Perroti(Memorial Sloan Kettering Cancer Center), Andrea M. Lewis(Baylor College of Medicine), Warren D.W. Heston(Cleveland Clinic), Robert Huyrk(Memorial Sloan Kettering Cancer Center), Jean Coke(Memorial Sloan Kettering Cancer Center)
Cited by 26
Related Papers
Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update
|The Journal of Urology|2007|1.1k
Variation in the Definition of Biochemical Recurrence in Patients Treated for Localized Prostate Cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel Report and Recommendations for a Standard in the Reporting of Surgical Outcomes
|The Journal of Urology|2007|845
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
|The Lancet|2018|779
The Treated Natural History of High Risk Superficial Bladder Cancer: 15-year Outcome
|The Journal of Urology|1997|555